S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

AngioDynamics Stock Forecast, Price & News

-1.63 (-5.65%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
118,414 shs
Average Volume
262,177 shs
Market Capitalization
$1.05 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

AngioDynamics logo

About AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$291.01 million
Cash Flow
$0.69 per share
Book Value
$11.52 per share


Net Income
$-31.55 million
Pretax Margin




Free Float
Market Cap
$1.05 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.40 out of 5 stars

Medical Sector

361st out of 1,392 stocks

Surgical & Medical Instruments Industry

35th out of 125 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

Is AngioDynamics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AngioDynamics stock.
View analyst ratings for AngioDynamics
or view top-rated stocks.

How has AngioDynamics' stock been impacted by COVID-19?

AngioDynamics' stock was trading at $10.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ANGO shares have increased by 168.4% and is now trading at $27.22.
View which stocks have been most impacted by COVID-19

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release its next quarterly earnings announcement on Thursday, January 6th 2022.
View our earnings forecast for AngioDynamics

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Thursday, September, 30th. The medical instruments supplier reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.03. The medical instruments supplier earned $77 million during the quarter, compared to analysts' expectations of $71.31 million. AngioDynamics had a negative net margin of 11.50% and a positive trailing twelve-month return on equity of 0.08%. AngioDynamics's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.02 EPS.
View AngioDynamics' earnings history

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY 2022 earnings guidance on Thursday, October, 28th. The company provided earnings per share guidance of $0.000-$0.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.010. The company issued revenue guidance of $310 million-$315 million, compared to the consensus revenue estimate of $307.82 million.

What price target have analysts set for ANGO?

3 brokers have issued 1-year target prices for AngioDynamics' stock. Their forecasts range from $32.00 to $37.00. On average, they anticipate AngioDynamics' stock price to reach $34.50 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price.
View analysts' price targets for AngioDynamics
or view top-rated stocks among Wall Street analysts.

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the following people:
  • James Christopher Clemmer, President, Chief Executive Officer & Director
  • David D. Helsel, SVP-Global Operations, Research & Development (LinkedIn Profile)
  • Stephen A. Trowbridge, Chief Financial Officer & Executive Vice President
  • Kim L. Seabury, Senior Vice President-Information Technology
  • Juan Carlos Serna, Senior VP-Scientific & Clinical Affairs

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

27 employees have rated AngioDynamics CEO James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among AngioDynamics' employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.15%), Dimensional Fund Advisors LP (7.22%), Victory Capital Management Inc. (5.97%), Polar Capital Holdings Plc (3.43%), Geode Capital Management LLC (1.69%) and The Manufacturers Life Insurance Company (1.58%). Company insiders that own AngioDynamics stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends for AngioDynamics

Which institutional investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., The Manufacturers Life Insurance Company , GSA Capital Partners LLP, Bank of New York Mellon Corp, Dimensional Fund Advisors LP, Russell Investments Group Ltd., and Victory Capital Management Inc.. Company insiders that have sold AngioDynamics company stock in the last year include Chad Thomas Campbell, Dave Helsel, Scott Centea, and Wesley Johnson.
View insider buying and selling activity for AngioDynamics
or view top insider-selling stocks.

Which institutional investors are buying AngioDynamics stock?

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, Goldman Sachs Group Inc., Invesco Ltd., Balyasny Asset Management LLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Tamarack Advisers LP, and Cinctive Capital Management LP. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics
or or view top insider-buying stocks.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $27.22.

How much money does AngioDynamics make?

AngioDynamics has a market capitalization of $1.05 billion and generates $291.01 million in revenue each year. The medical instruments supplier earns $-31.55 million in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does AngioDynamics have?

AngioDynamics employs 800 workers across the globe.

Does AngioDynamics have any subsidiaries?

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.

When was AngioDynamics founded?

AngioDynamics was founded in 1988.

What is AngioDynamics' official website?

The official website for AngioDynamics is www.angiodynamics.com.

Where are AngioDynamics' headquarters?

AngioDynamics is headquartered at 14 PLAZA DRIVE, LATHAM NY, 12110.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at [email protected], or via fax at 518-795-1401.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.